Vitor Alves Cruz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Vitor Alves Cruz has a total of 267 co-authors. Here are the top co-authors by number of shared publications:
- Viviane Angelina de Souza
Faculdade de Medicina, Universidade Federal de Juiz de Fora, Juiz de Fora 36036-900, MG, Brazil
12 shared publications - Gecilmara Salviato Pileggi
Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo 04023-062, SP, Brazil
11 shared publications - Gilda Aparecida Ferreira
Locomotor System Department, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte 30130-100, MG, Brazil
11 shared publications - Odirlei André Monticielo
Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre 90010-150, RS, Brazil
11 shared publications - Ricardo Machado Xavier
Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
11 shared publications - Rodrigo Poubel Vieira de Rezende
Universidade Federal Fluminense, Brazil
11 shared publications
Latest Publications
- Open Access
Immunogenicity, Safety, and Clinical Outcomes Following Homologous and Heterologous SARS-CoV-2 Vaccination Regimens in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: A Prospective Observational Study from the SAFER Cohort
Background/Objectives: Patients with spondyloarthritis (SpA) frequently receive immunomodulatory therapies that may influence vaccine-induced immune responses. However, evidence comparing the immunogenicity, safety, and clinical outcomes following homologous and heterologous SARS-CoV-2 vaccination regimens in axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) remains limited. Methods: This observational study was conducted within the Brazilian multicenter SAFER cohort and included adults with axSpA or PsA who received three doses of SARS-CoV-2 vaccines through the Brazilian National Immunization Program. The primary outcome was humoral immunogenicity, assessed by anti-receptor-binding domain (anti-RBD) IgG geometric mean titers (GMTs). Clinical outcomes, disease activity, and safety were evaluated throughout follow-up. Results: Ninety patients (axSpA = 69; PsA = 21) were included. Antibody titers increased progressively after vaccination, with GMTs rising from 6.70 BAU/mL at baseline to 907.72 BAU/mL after the additional dose. Humoral responses were comparable between axSpA and PsA throughout follow-up. Participants with previous SARS-CoV-2 exposure consistently exhibited higher antibody responses than infection-naïve individuals. Although ChAdOx1-S elicited stronger early humoral responses than CoronaVac, heterologous regimens incorporating a BNT162b2 additional dose produced the highest post-additional-dose antibody concentrations. Serological response rates reached 100% after the additional dose, irrespective of disease subtype or vaccination regimen. Biologic disease-modifying antirheumatic drugs (bDMARDs), including TNF inhibitors, were not significantly associated with reduced antibody responses. Only four COVID-19 cases occurred during follow-up, with no hospitalizations or deaths. Disease activity remained stable, and adverse events were predominantly mild and self-limited. Conclusions: SARS-CoV-2 vaccination was safe and highly immunogenic in patients with axSpA and PsA, without compromising disease activity control. Heterologous vaccination regimens incorporating a BNT162b2 additional dose elicited the strongest humoral immune responses. These findings provide prospective real-world evidence supporting optimized additional-dose strategies and may inform future vaccination approaches for patients with SpA.
Open AccessImmunogenicity, Safety, and Clinical Outcomes Following Homologous and Heterologous SARS-CoV-2 Vaccination Regimens in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: A Prospective Observational Study from the SAFER Cohort
Background/Objectives: Patients with spondyloarthritis (SpA) frequently receive immunomodulatory therapies that may influence vaccine-induced immune responses. However, evidence comparing the immunogenicity, safety, and clinical outcomes following homologous and heterologous SARS-CoV-2 vaccination regimens in axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) remains limited. Methods: This observational study was conducted within the Brazilian multicenter SAFER cohort and included adults with axSpA or PsA who received three doses of SARS-CoV-2 vaccines through the Brazilian National Immunization Program. The primary outcome was humoral immunogenicity, assessed by anti-receptor-binding domain (anti-RBD) IgG geometric mean titers (GMTs). Clinical outcomes, disease activity, and safety were evaluated throughout follow-up. Results: Ninety patients (axSpA = 69; PsA = 21) were included. Antibody titers increased progressively after vaccination, with GMTs rising from 6.70 BAU/mL at baseline to 907.72 BAU/mL after the additional dose. Humoral responses were comparable between axSpA and PsA throughout follow-up. Participants with previous SARS-CoV-2 exposure consistently exhibited higher antibody responses than infection-naïve individuals. Although ChAdOx1-S elicited stronger early humoral responses than CoronaVac, heterologous regimens incorporating a BNT162b2 additional dose produced the highest post-additional-dose antibody concentrations. Serological response rates reached 100% after the additional dose, irrespective of disease subtype or vaccination regimen. Biologic disease-modifying antirheumatic drugs (bDMARDs), including TNF inhibitors, were not significantly associated with reduced antibody responses. Only four COVID-19 cases occurred during follow-up, with no hospitalizations or deaths. Disease activity remained stable, and adverse events were predominantly mild and self-limited. Conclusions: SARS-CoV-2 vaccination was safe and highly immunogenic in patients with axSpA and PsA, without compromising disease activity control. Heterologous vaccination regimens incorporating a BNT162b2 additional dose elicited the strongest humoral immune responses. These findings provide prospective real-world evidence supporting optimized additional-dose strategies and may inform future vaccination approaches for patients with SpA.
- Open Access
- 21 September 2026
- Published by Springer Nature in Advances in Rheumatology
Beyond strongyloides: rationale for empirical antiparasitic prophylaxis in immunosuppressed patients with rheumatic diseases in endemic areas
Background: Intestinal parasitic infections remain highly prevalent in endemic regions such as Brazil and pose a significant risk to patients with immune-mediated rheumatic diseases (IMRDs) undergoing immunosuppressive therapy. Immunosuppression may alter the natural history of parasitic infections, particularly Strongyloides stercoralis , increasing the risk of hyperinfection and disseminated disease with high mortality. Objective: To provide a narrative review of the epidemiological, clinical, and pharmacological evidence supporting empirical antiparasitic prophylaxis in immunosuppressed patients with rheumatic diseases in endemic settings—highlighting ivermectin as the cornerstone for Strongyloides stercoralis prevention and the role of complementary broad-spectrum agents, such as albendazole or nitazoxanide—and to propose a practical, context-adapted preventive approach. Methods: A narrative review of the literature was conducted, integrating data from epidemiological studies, clinical reports, reviews, and international and national recommendations addressing intestinal parasitic infections, immunosuppression, screening strategies, and preventive chemotherapy in endemic and non-endemic settings. Results: Available evidence demonstrates persistent endemicity, frequent polyparasitism, and substantial diagnostic limitations in detecting latent or low-burden infections in endemic regions. Strongyloides stercoralis represents the main risk for severe and disseminated disease under immunosuppression, supporting the use of ivermectin (200 µg/kg/day for two consecutive days) as the cornerstone of prophylaxis. However, given its limited activity against other soil-transmitted helminths (e.g., Ascaris lumbricoides , Ancylostoma/Necator species) and intestinal protozoa (e.g., Giardia intestinalis and Entamoeba histolytica ), complementary agents such as albendazole (400 mg daily for 3–5 days) or nitazoxanide (500 mg twice daily for 3 days) are proposed to broaden coverage. Empirical combination prophylaxis prior to immunosuppression may be considered in selected patients with substantial epidemiological risk, while periodic repetition in those with ongoing exposure should be individualized given the limited direct evidence supporting this strategy. Conclusions: In endemic settings, empirical combined antiparasitic prophylaxis may represent a pragmatic, context-adapted option for selected patients undergoing immunosuppressive therapy. Although not a formal guideline, this strategy offers a technically grounded framework to support individualized clinical decision-making and to mitigate the burden of intestinal parasitic infections in vulnerable populations.
- 21 September 2026
- Published by Springer Nature in Advances in Rheumatology
Open AccessBeyond strongyloides: rationale for empirical antiparasitic prophylaxis in immunosuppressed patients with rheumatic diseases in endemic areas
Background: Intestinal parasitic infections remain highly prevalent in endemic regions such as Brazil and pose a significant risk to patients with immune-mediated rheumatic diseases (IMRDs) undergoing immunosuppressive therapy. Immunosuppression may alter the natural history of parasitic infections, particularly Strongyloides stercoralis , increasing the risk of hyperinfection and disseminated disease with high mortality. Objective: To provide a narrative review of the epidemiological, clinical, and pharmacological evidence supporting empirical antiparasitic prophylaxis in immunosuppressed patients with rheumatic diseases in endemic settings—highlighting ivermectin as the cornerstone for Strongyloides stercoralis prevention and the role of complementary broad-spectrum agents, such as albendazole or nitazoxanide—and to propose a practical, context-adapted preventive approach. Methods: A narrative review of the literature was conducted, integrating data from epidemiological studies, clinical reports, reviews, and international and national recommendations addressing intestinal parasitic infections, immunosuppression, screening strategies, and preventive chemotherapy in endemic and non-endemic settings. Results: Available evidence demonstrates persistent endemicity, frequent polyparasitism, and substantial diagnostic limitations in detecting latent or low-burden infections in endemic regions. Strongyloides stercoralis represents the main risk for severe and disseminated disease under immunosuppression, supporting the use of ivermectin (200 µg/kg/day for two consecutive days) as the cornerstone of prophylaxis. However, given its limited activity against other soil-transmitted helminths (e.g., Ascaris lumbricoides , Ancylostoma/Necator species) and intestinal protozoa (e.g., Giardia intestinalis and Entamoeba histolytica ), complementary agents such as albendazole (400 mg daily for 3–5 days) or nitazoxanide (500 mg twice daily for 3 days) are proposed to broaden coverage. Empirical combination prophylaxis prior to immunosuppression may be considered in selected patients with substantial epidemiological risk, while periodic repetition in those with ongoing exposure should be individualized given the limited direct evidence supporting this strategy. Conclusions: In endemic settings, empirical combined antiparasitic prophylaxis may represent a pragmatic, context-adapted option for selected patients undergoing immunosuppressive therapy. Although not a formal guideline, this strategy offers a technically grounded framework to support individualized clinical decision-making and to mitigate the burden of intestinal parasitic infections in vulnerable populations.
- Open Access
- 24 August 2026
- Published by Springer Nature in Advances in Rheumatology
Factors associated with discordance between the patient-reported Rheumatoid Arthritis Disease Activity Index (RADAI) and the Simplified Disease Activity Index (SDAI) concerning the achievement of treat-to-target goals – data from the REAL study
Background: Treat-to-target (T2T) strategies in rheumatoid arthritis (RA) rely on regular assessment of disease activity using validated composite indices, with remission or low disease activity as therapeutic goals. The Simplified Disease Activity Index (SDAI) is widely recommended for this purpose. With the expansion of telemedicine and patient-centered care, self-administered tools such as the Rheumatoid Arthritis Disease Activity Index (RADAI) have gained relevance. However, discordance between patient-reported and composite disease activity measures may affect the interpretation of T2T achievement. Objective: To assess RADAI/SDAI concordance regarding T2T status among patients with RA who had achieved remission or low disease activity according to SDAI (SDAI < 11), and to identify factors associated with discordance. Methods: This cross-sectional sub-analysis of the multicenter REAL study included patients with RA from 11 Brazilian public hospitals who had SDAI < 11 at baseline. Participants were classified as concordant when RADAI also indicated achievement of the T2T goal (RADAI < 2.2) and discordant when RADAI indicated moderate or high disease activity (RADAI ≥ 2.2). Logistic regression was used to identify factors independently associated with discordance. Results: Among 485 participants with SDAI < 11, 89.9% ( n = 436) were female, 61.2% ( n = 297) were white, and the mean (SD) age was 57.0 (11.4) years. RADAI classification was concordant with SDAI-defined T2T status in 63.9% ( n = 310) and discordant in 36.1% ( n = 175). In multivariable analysis, corticosteroid use (OR 2.62; 95% CI 1.29–5.29; p = 0.007), joint pain intensity (OR 1.05; 95% CI 1.03–1.07; p < 0.001), patient global assessment (OR 1.12; 95% CI 1.08–1.16; p < 0.001), and disability assessed by HAQ (OR 2.32; 95% CI 1.24–4.26; p = 0.006) were independently associated with discordance. Conclusion: More than one-third of patients who had achieved SDAI-defined T2T goals were classified by RADAI as having moderate or high disease activity. Discordance was associated predominantly with patient-reported symptoms and functional disability. These findings suggest that SDAI and RADAI capture partially different and complementary dimensions of disease burden and should be interpreted within the broader clinical context. Clinical trial number: Not applicable.
- 24 August 2026
- Published by Springer Nature in Advances in Rheumatology
Open AccessFactors associated with discordance between the patient-reported Rheumatoid Arthritis Disease Activity Index (RADAI) and the Simplified Disease Activity Index (SDAI) concerning the achievement of treat-to-target goals – data from the REAL study
Background: Treat-to-target (T2T) strategies in rheumatoid arthritis (RA) rely on regular assessment of disease activity using validated composite indices, with remission or low disease activity as therapeutic goals. The Simplified Disease Activity Index (SDAI) is widely recommended for this purpose. With the expansion of telemedicine and patient-centered care, self-administered tools such as the Rheumatoid Arthritis Disease Activity Index (RADAI) have gained relevance. However, discordance between patient-reported and composite disease activity measures may affect the interpretation of T2T achievement. Objective: To assess RADAI/SDAI concordance regarding T2T status among patients with RA who had achieved remission or low disease activity according to SDAI (SDAI < 11), and to identify factors associated with discordance. Methods: This cross-sectional sub-analysis of the multicenter REAL study included patients with RA from 11 Brazilian public hospitals who had SDAI < 11 at baseline. Participants were classified as concordant when RADAI also indicated achievement of the T2T goal (RADAI < 2.2) and discordant when RADAI indicated moderate or high disease activity (RADAI ≥ 2.2). Logistic regression was used to identify factors independently associated with discordance. Results: Among 485 participants with SDAI < 11, 89.9% ( n = 436) were female, 61.2% ( n = 297) were white, and the mean (SD) age was 57.0 (11.4) years. RADAI classification was concordant with SDAI-defined T2T status in 63.9% ( n = 310) and discordant in 36.1% ( n = 175). In multivariable analysis, corticosteroid use (OR 2.62; 95% CI 1.29–5.29; p = 0.007), joint pain intensity (OR 1.05; 95% CI 1.03–1.07; p < 0.001), patient global assessment (OR 1.12; 95% CI 1.08–1.16; p < 0.001), and disability assessed by HAQ (OR 2.32; 95% CI 1.24–4.26; p = 0.006) were independently associated with discordance. Conclusion: More than one-third of patients who had achieved SDAI-defined T2T goals were classified by RADAI as having moderate or high disease activity. Discordance was associated predominantly with patient-reported symptoms and functional disability. These findings suggest that SDAI and RADAI capture partially different and complementary dimensions of disease burden and should be interpreted within the broader clinical context. Clinical trial number: Not applicable.
- Open Access
- 13 March 2026
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Are global definitions enough? Revisiting CDAI and SDAI remission cut-offs in Brazilian Rheumatoid Arthritis patients
Background: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease in which achieving remission is the most effective strategy to prevent progression and optimize long-term outcomes. The performance of commonly used disease activity indices has not been well validated in the Brazilian RA population. This study aimed to evaluate the agreement between CDAI/SDAI and the revised Boolean 2.0 remission criteria, which served as the reference standard, and to identify the most accurate CDAI and SDAI remission cut-offs in this population. Methods: We conducted a cross-sectional analysis of baseline data from a Brazilian Cohort study, which included 840 patients from 11 public hospitals in Brazil. Disease activity was assessed using DAS28-CRP, DAS28-ESR, SDAI, CDAI, and Boolean 1.0/2.0. Agreement was assessed using Cohen’s kappa, and optimal remission cut-offs were determined through ROC curve analysis. Results: The study population was predominantly female (89.8%), with a mean age of 57 years and a median disease duration of 12 years. DAS28-CRP showed the highest remission rate (39.2%), whereas Boolean 1.0 showed the lowest (15.1%). Strong agreement was found between Boolean 2.0, and both the SDAI (κ = 0.775) and CDAI (κ = 0.692). ROC analysis revealed that the most accurate remission cut-offs were SDAI ≤ 4.3 and CDAI ≤ 3.9, which increased remission detection by 5.9% and 6.2%, respectively. Conclusion: In our cohort, SDAI ≤ 4.3 and CDAI ≤ 3.9 were the values most closely aligned with Boolean 2.0 remission. These adjusted cut-offs may help minimize overtreatment in resource-limited settings. Prospective studies assessing function, radiographic progression, and quality of life are warranted to confirm their validity in the Brazilian population.
- 13 March 2026
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Open AccessAre global definitions enough? Revisiting CDAI and SDAI remission cut-offs in Brazilian Rheumatoid Arthritis patients
Background: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease in which achieving remission is the most effective strategy to prevent progression and optimize long-term outcomes. The performance of commonly used disease activity indices has not been well validated in the Brazilian RA population. This study aimed to evaluate the agreement between CDAI/SDAI and the revised Boolean 2.0 remission criteria, which served as the reference standard, and to identify the most accurate CDAI and SDAI remission cut-offs in this population. Methods: We conducted a cross-sectional analysis of baseline data from a Brazilian Cohort study, which included 840 patients from 11 public hospitals in Brazil. Disease activity was assessed using DAS28-CRP, DAS28-ESR, SDAI, CDAI, and Boolean 1.0/2.0. Agreement was assessed using Cohen’s kappa, and optimal remission cut-offs were determined through ROC curve analysis. Results: The study population was predominantly female (89.8%), with a mean age of 57 years and a median disease duration of 12 years. DAS28-CRP showed the highest remission rate (39.2%), whereas Boolean 1.0 showed the lowest (15.1%). Strong agreement was found between Boolean 2.0, and both the SDAI (κ = 0.775) and CDAI (κ = 0.692). ROC analysis revealed that the most accurate remission cut-offs were SDAI ≤ 4.3 and CDAI ≤ 3.9, which increased remission detection by 5.9% and 6.2%, respectively. Conclusion: In our cohort, SDAI ≤ 4.3 and CDAI ≤ 3.9 were the values most closely aligned with Boolean 2.0 remission. These adjusted cut-offs may help minimize overtreatment in resource-limited settings. Prospective studies assessing function, radiographic progression, and quality of life are warranted to confirm their validity in the Brazilian population.
- Open Access
- 23 January 2026
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Brazilian Society of Rheumatology – 2025 recommendations on vaccination in immune-mediated rheumatic diseases
Background: Patients with immune-mediated rheumatic diseases (IMRD) are at increased risk for infections due to both disease-related immune dysregulation and immunosuppressive therapy. Despite the benefits of vaccination, immunization rates in this population remain suboptimal, often due to concerns about safety, efficacy, and their potential for inducing disease flare. Regional-specific guidelines are necessary to address the particular epidemiological issues and aspects of the healthcare systems, especially in countries like Brazil. Objective: To provide updated, evidence-based, and nationally relevant recommendations on vaccination in adult patients with IMRD in Brazil, focusing on immunogenicity, safety and disease activity outcomes. Methods: A multidisciplinary task force from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis of studies addressing eleven clinical questions related to vaccine safety and efficacy in IMRD. Studies were selected using predefined PICO criteria. Risk of bias was assessed using JBI tools, and the certainty of evidence was evaluated with the GRADE approach. Statements were developed and submitted to a Delphi-based voting process; consensus was achieved if ≥80% of the panelists voted “agree” or “strongly agree” for all the statements. Results: Eleven recommendations were developed based on a systematic review of the literature, with meta-analyses conducted when appropriate. Inactivated vaccines demonstrated a favorable safety profile, with low flare rates and no significant increase in disease activity, even under immunosuppression. Live attenuated vaccines, including yellow fever, were considered safe when administered according to timing protocols. Immunogenicity may be reduced in patients receiving methotrexate, mycophenolate, corticosteroids, rituximab, and JAK inhibitors, although this does not appear to compromise clinical protection in most cases. Temporary treatment interruption was associated with improved immunogenicity in selected contexts, but without consistent evidence of clinical benefit and with potential risks related to disease control. Specific guidance was provided for influenza and hepatitis B vaccination, as well as for prioritizing vaccination before initiating immunosuppression whenever feasible. Statements also addressed the approach to revaccination and post-vaccination serologic testing. Despite the overall very low to moderate certainty of evidence, most recommendations reached strong consensus (≥80% agreement). Shared decision-making and individualized strategies were emphasized across all scenarios. Conclusion: These recommendations offer tailored guidance for improving vaccination strategies in IMRD patients in Brazil. Given the heterogeneity of evidence, clinical decisions should be individualized, considering disease activity, treatment regimen, vaccine availability, and patient preferences. Shared decision-making is essential in all scenarios to enhance vaccine uptake and align preventive care with patient-centered management.
- 23 January 2026
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Open AccessBrazilian Society of Rheumatology – 2025 recommendations on vaccination in immune-mediated rheumatic diseases
Background: Patients with immune-mediated rheumatic diseases (IMRD) are at increased risk for infections due to both disease-related immune dysregulation and immunosuppressive therapy. Despite the benefits of vaccination, immunization rates in this population remain suboptimal, often due to concerns about safety, efficacy, and their potential for inducing disease flare. Regional-specific guidelines are necessary to address the particular epidemiological issues and aspects of the healthcare systems, especially in countries like Brazil. Objective: To provide updated, evidence-based, and nationally relevant recommendations on vaccination in adult patients with IMRD in Brazil, focusing on immunogenicity, safety and disease activity outcomes. Methods: A multidisciplinary task force from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis of studies addressing eleven clinical questions related to vaccine safety and efficacy in IMRD. Studies were selected using predefined PICO criteria. Risk of bias was assessed using JBI tools, and the certainty of evidence was evaluated with the GRADE approach. Statements were developed and submitted to a Delphi-based voting process; consensus was achieved if ≥80% of the panelists voted “agree” or “strongly agree” for all the statements. Results: Eleven recommendations were developed based on a systematic review of the literature, with meta-analyses conducted when appropriate. Inactivated vaccines demonstrated a favorable safety profile, with low flare rates and no significant increase in disease activity, even under immunosuppression. Live attenuated vaccines, including yellow fever, were considered safe when administered according to timing protocols. Immunogenicity may be reduced in patients receiving methotrexate, mycophenolate, corticosteroids, rituximab, and JAK inhibitors, although this does not appear to compromise clinical protection in most cases. Temporary treatment interruption was associated with improved immunogenicity in selected contexts, but without consistent evidence of clinical benefit and with potential risks related to disease control. Specific guidance was provided for influenza and hepatitis B vaccination, as well as for prioritizing vaccination before initiating immunosuppression whenever feasible. Statements also addressed the approach to revaccination and post-vaccination serologic testing. Despite the overall very low to moderate certainty of evidence, most recommendations reached strong consensus (≥80% agreement). Shared decision-making and individualized strategies were emphasized across all scenarios. Conclusion: These recommendations offer tailored guidance for improving vaccination strategies in IMRD patients in Brazil. Given the heterogeneity of evidence, clinical decisions should be individualized, considering disease activity, treatment regimen, vaccine availability, and patient preferences. Shared decision-making is essential in all scenarios to enhance vaccine uptake and align preventive care with patient-centered management.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista Brasileira de Epidemiologia
- Vol. 29
COVID-19 vaccine effectiveness against in-hospital mortality in immunocompromised older adults: a Brazilian hospital surveillance study, 2024
Objective: The study evaluated the association between COVID-19 vaccination and in-hospital mortality among immunocompromised older adults hospitalized for COVID-19 in Brazil during the 2024 epidemiologic year. Methods: This retrospective hospital-based surveillance study used data from the Brazilian SIVEP-Gripe database. All hospitalized cases of COVID-19-related severe acute respiratory syndrome in immunocompromised individuals aged ≥60 years reported during epidemiological weeks 1–52 of 2024 were included. Multivariable logistic regression was used to estimate odds ratio (OR) and 95% confidence interval (95%CI) for the association between COVID-19 vaccination (number of doses) and in-hospital mortality, adjusting for clinical and sociodemographic covariates. Results: Among 474 patients, in-hospital mortality was 36% (171/474). Only 56 (12%) were unvaccinated. Compared with unvaccinated individuals, adjusted ORs for mortality were 0.67 (95%CI 0.32–1.39) for 1–2 doses, 0.67 (95%CI 0.31–1.42) for 3 doses, 0.54 (95%CI 0.26–1.15) for 4 doses, and 0.56 (95%CI 0.26–1.17) for 5–6 doses. Mechanical ventilation (OR 12.55; 95%CI 6.39–26.33) and lower educational attainment (elementary education: OR 2.94; 95%CI 1.39–6.44) were independent predictors of death. COVID-19 vaccination was not significantly associated with reduced in-hospital mortality among immunocompromised older adults hospitalized for the disease in Brazil in 2024. However, all adjusted ORs were below unity, suggesting a trend toward protection with increasing doses. Conclusions: The strong association of mortality with mechanical ventilation and social determinants highlights the need for timely boosters and comprehensive preventive strategies for this vulnerable population.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista Brasileira de Epidemiologia
- Vol. 29
Open AccessCOVID-19 vaccine effectiveness against in-hospital mortality in immunocompromised older adults: a Brazilian hospital surveillance study, 2024
Objective: The study evaluated the association between COVID-19 vaccination and in-hospital mortality among immunocompromised older adults hospitalized for COVID-19 in Brazil during the 2024 epidemiologic year. Methods: This retrospective hospital-based surveillance study used data from the Brazilian SIVEP-Gripe database. All hospitalized cases of COVID-19-related severe acute respiratory syndrome in immunocompromised individuals aged ≥60 years reported during epidemiological weeks 1–52 of 2024 were included. Multivariable logistic regression was used to estimate odds ratio (OR) and 95% confidence interval (95%CI) for the association between COVID-19 vaccination (number of doses) and in-hospital mortality, adjusting for clinical and sociodemographic covariates. Results: Among 474 patients, in-hospital mortality was 36% (171/474). Only 56 (12%) were unvaccinated. Compared with unvaccinated individuals, adjusted ORs for mortality were 0.67 (95%CI 0.32–1.39) for 1–2 doses, 0.67 (95%CI 0.31–1.42) for 3 doses, 0.54 (95%CI 0.26–1.15) for 4 doses, and 0.56 (95%CI 0.26–1.17) for 5–6 doses. Mechanical ventilation (OR 12.55; 95%CI 6.39–26.33) and lower educational attainment (elementary education: OR 2.94; 95%CI 1.39–6.44) were independent predictors of death. COVID-19 vaccination was not significantly associated with reduced in-hospital mortality among immunocompromised older adults hospitalized for the disease in Brazil in 2024. However, all adjusted ORs were below unity, suggesting a trend toward protection with increasing doses. Conclusions: The strong association of mortality with mechanical ventilation and social determinants highlights the need for timely boosters and comprehensive preventive strategies for this vulnerable population.
- Open Access
- 22 November 2025
- Published by Springer Nature in Advances in Rheumatology
- Vol. 65 (1)
Comparison of the immunogenicity and safety among COVID-19 vaccines ChadOx-1, CoronaVac and BNT162b2 in systemic lupus erythematosus (SLE) patients: a prospective cohort
Background: The immune response and safety using different COVID-19 vaccine platforms in patients with immune mediated rheumatic diseases is still uncertain. The objective of this study is to compare the immunogenicity and safety after two doses of BNT162b2, CoronaVac and ChadOx-1 in SLE patients. Methods: Prospective study including SLE patients who received a primary schedule to COVID-19 vaccination between May and August 2021. Immunogenicity, events supposedly attributable to vaccination or immunization (ESAVI) and disease activity were assessed at baseline and after each vaccine dose. Results: 121 SLE patients were included in the cohort, 88 in the immunogenicity analysis and 118 in the safety analysis. The groups were homogenous concerning sex, age, and comorbidities. Seropositivity after two doses of vaccines was similar between CoronaVac (68%), ChadOx1 (80,6%) and BNT162b2 (88%) (p=0.231). However, CoronaVac and ChadOx-1 presented lower titers in comparison with BNT162b2. Regarding ESAVI, the most frequent reported following first and second vaccine doses were, respectively: injection site pain (65.2%/41.1%), headache (50.9%/29.9%) and arthralgia (37.5%/22.5%). Fever and myalgia were more related to ChAdOx1 than CoronaVac (23.3 vs. 5.0%; p=0.025). There was no difference in MEX-SLEDAI between vaccine platforms. No serious ESAVI were reported. Conclusion: After two doses, the three COVID-19 vaccine platforms induced a significant increase in antibody titers against SARS-CoV-2. Patients who received BNT162b2 exhibited a higher serological response compared to the other vaccines. All three vaccine platforms demonstrated a favorable safety profile, with no serious ESAVI or worsening of disease activity. Clinical trial Number: The study was registered in The Brazilian Registry of Clinical Trials (ReBEC) in 04/14/2021 with code RBR-108fyykd.
- 22 November 2025
- Published by Springer Nature in Advances in Rheumatology
- Vol. 65 (1)
Open AccessComparison of the immunogenicity and safety among COVID-19 vaccines ChadOx-1, CoronaVac and BNT162b2 in systemic lupus erythematosus (SLE) patients: a prospective cohort
Background: The immune response and safety using different COVID-19 vaccine platforms in patients with immune mediated rheumatic diseases is still uncertain. The objective of this study is to compare the immunogenicity and safety after two doses of BNT162b2, CoronaVac and ChadOx-1 in SLE patients. Methods: Prospective study including SLE patients who received a primary schedule to COVID-19 vaccination between May and August 2021. Immunogenicity, events supposedly attributable to vaccination or immunization (ESAVI) and disease activity were assessed at baseline and after each vaccine dose. Results: 121 SLE patients were included in the cohort, 88 in the immunogenicity analysis and 118 in the safety analysis. The groups were homogenous concerning sex, age, and comorbidities. Seropositivity after two doses of vaccines was similar between CoronaVac (68%), ChadOx1 (80,6%) and BNT162b2 (88%) (p=0.231). However, CoronaVac and ChadOx-1 presented lower titers in comparison with BNT162b2. Regarding ESAVI, the most frequent reported following first and second vaccine doses were, respectively: injection site pain (65.2%/41.1%), headache (50.9%/29.9%) and arthralgia (37.5%/22.5%). Fever and myalgia were more related to ChAdOx1 than CoronaVac (23.3 vs. 5.0%; p=0.025). There was no difference in MEX-SLEDAI between vaccine platforms. No serious ESAVI were reported. Conclusion: After two doses, the three COVID-19 vaccine platforms induced a significant increase in antibody titers against SARS-CoV-2. Patients who received BNT162b2 exhibited a higher serological response compared to the other vaccines. All three vaccine platforms demonstrated a favorable safety profile, with no serious ESAVI or worsening of disease activity. Clinical trial Number: The study was registered in The Brazilian Registry of Clinical Trials (ReBEC) in 04/14/2021 with code RBR-108fyykd.
- Open Access
Primary and Booster COVID-19 Vaccination in Patients with Sjögren’s Disease: Data from the Longitudinal SAFER Cohort Study
Introduction: The COVID-19 pandemic posed additional challenges for this vulnerable population, such as Sjögren’s disease (SjD), underscoring the need for effective and safe vaccination strategies. Objective: To evaluate the immunogenicity and safety of COVID-19 vaccines in patients with SjD. Methods: This prospective, observational, longitudinal study included SjD patients from the SAFER cohort. Immunogenicity was assessed via anti-spike IgG (IgG-S) titers using chemiluminescence reported as geometric mean titers (GMT) and fold increase in GMT (FI-GMT). Disease activity was evaluated using the ESSDAI score. Adverse events and COVID-19 infections were also monitored. Assessments were conducted at four time points: pre-first dose (T1), pre-second dose (T2), pre-booster (T3), and four weeks post-booster (T4). Primary vaccination involved ChAdOx1 nCoV-19 or inactivated vaccine (CoronaVac), and boosters were either homologous (ChAdOx1 nCoV-19) or heterologous (BNT162b2). Results: Among 51 participants (mean age 46 years; 90% female), 41% had comorbidities and 27% (n = 14/51) were highly immunosuppressed. Among those 73% (n = 37/51) under low immunosuppression, n = 8/51 (13%) were not using any medication. At baseline, 11% (n = 4/35) showed moderate/high disease activity, which decreased to 6.5% (n = 2/31) at T4. Primary vaccination was ChAdOx1 in 94% (n = 48/51) and CoronaVac in 6% (n = 3/51); 73% (n = 37/51) received heterologous and 27% (n = 14/51) homologous boosters. COVID-19 infection post-booster occurred in 20% (n = 10/51). Seroconversion rates reached nearly 100% across all medication subgroups except for biologic users, who showed delayed but stable seroconversion by T4. IgG-S titers increased progressively through T4. Primary immunization induced an ascending GMT in both vaccine types. At T4, the GMT was significantly higher in the BNT162b2 group (2148.03 [1452.05–3155.84]; p < 0.001; 95% CI) than in the ChAdOx1 group (324.29 [107.92–974.48]; p < 0.001; 95% CI); the fold-increase in immune response was six times greater with BNT162b2 (5.98 [2.97–12.03]; p = 0.001; 95% CI). Seroconversion was 100% in the heterologous group versus 83% in the homologous group (p > 0.01). Those with prior infection showed significantly higher titers, particularly at T2 and T3 (p < 0.001 for T1–T3). Adverse events were mild and not statistically significant. Multivariate regression confirmed BNT162b2 as an independent factor for higher antibody titers. Conclusion: COVID-19 vaccination in patients with SjD was safe and induced high anti-spike antibody titers and seropositivity. Heterologous boosting, particularly with BNT162b2, demonstrated superior immunogenicity. No association was found between vaccination and SjD disease flares or worsening activity.
Open AccessPrimary and Booster COVID-19 Vaccination in Patients with Sjögren’s Disease: Data from the Longitudinal SAFER Cohort Study
Introduction: The COVID-19 pandemic posed additional challenges for this vulnerable population, such as Sjögren’s disease (SjD), underscoring the need for effective and safe vaccination strategies. Objective: To evaluate the immunogenicity and safety of COVID-19 vaccines in patients with SjD. Methods: This prospective, observational, longitudinal study included SjD patients from the SAFER cohort. Immunogenicity was assessed via anti-spike IgG (IgG-S) titers using chemiluminescence reported as geometric mean titers (GMT) and fold increase in GMT (FI-GMT). Disease activity was evaluated using the ESSDAI score. Adverse events and COVID-19 infections were also monitored. Assessments were conducted at four time points: pre-first dose (T1), pre-second dose (T2), pre-booster (T3), and four weeks post-booster (T4). Primary vaccination involved ChAdOx1 nCoV-19 or inactivated vaccine (CoronaVac), and boosters were either homologous (ChAdOx1 nCoV-19) or heterologous (BNT162b2). Results: Among 51 participants (mean age 46 years; 90% female), 41% had comorbidities and 27% (n = 14/51) were highly immunosuppressed. Among those 73% (n = 37/51) under low immunosuppression, n = 8/51 (13%) were not using any medication. At baseline, 11% (n = 4/35) showed moderate/high disease activity, which decreased to 6.5% (n = 2/31) at T4. Primary vaccination was ChAdOx1 in 94% (n = 48/51) and CoronaVac in 6% (n = 3/51); 73% (n = 37/51) received heterologous and 27% (n = 14/51) homologous boosters. COVID-19 infection post-booster occurred in 20% (n = 10/51). Seroconversion rates reached nearly 100% across all medication subgroups except for biologic users, who showed delayed but stable seroconversion by T4. IgG-S titers increased progressively through T4. Primary immunization induced an ascending GMT in both vaccine types. At T4, the GMT was significantly higher in the BNT162b2 group (2148.03 [1452.05–3155.84]; p < 0.001; 95% CI) than in the ChAdOx1 group (324.29 [107.92–974.48]; p < 0.001; 95% CI); the fold-increase in immune response was six times greater with BNT162b2 (5.98 [2.97–12.03]; p = 0.001; 95% CI). Seroconversion was 100% in the heterologous group versus 83% in the homologous group (p > 0.01). Those with prior infection showed significantly higher titers, particularly at T2 and T3 (p < 0.001 for T1–T3). Adverse events were mild and not statistically significant. Multivariate regression confirmed BNT162b2 as an independent factor for higher antibody titers. Conclusion: COVID-19 vaccination in patients with SjD was safe and induced high anti-spike antibody titers and seropositivity. Heterologous boosting, particularly with BNT162b2, demonstrated superior immunogenicity. No association was found between vaccination and SjD disease flares or worsening activity.
- Open Access
Impact of SARS-CoV-2 Vaccination on Disease Activity and Severity of COVID-19 Infection in Patients with Systemic Lupus Erythematosus: A Multicenter Cohort Study
Background: To prospectively evaluate the safety and clinical impact of SARS-CoV-2 vaccines in patients with systemic lupus erythematosus (SLE). Methods: Subanalysis of the Brazilian multicenter observational study “Safety, Effectiveness and Duration of Immunity after Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Inflammatory Diseases (SAFER)”, which included SLE patients vaccinated with CoronaVac, ChAdOx1, or BNT162b2. Patients with HIV infection, pregnant women, or those with immunosuppression not related to SLE were excluded. Safety data related to adverse events and underlying disease activity were assessed. Additionally, COVID-19 cases were monitored throughout the follow-up period. Results: The study included 373 patients with systemic lupus erythematosus (SLE), with a mean age of 36 years, the majority being women (89.8%). The most common adverse events after SARS-CoV-2 vaccination were injection site reactions and headache, observed both after the first and subsequent doses. The ChAdOx-1 vaccine was associated with a higher frequency of adverse events compared to CoronaVac. At baseline, 38.3% of patients were in remission, 32.8% had low disease activity, and 28.9% had moderate to high activity. Following CoronaVac vaccination, there was an increase in remission rates (from 34.6% to 51.1%) and a significant reduction in moderate to high activity (from 37.6% to 15.0%) after the first dose, with this reduction partially maintained after the second dose. In contrast, patients vaccinated with ChAdOx-1 showed an increase in moderate to high activity (from 14.5% to 38.2% after the first dose), a trend that persisted after the second dose. No statistically significant changes in disease activity were observed among those who received BNT162b2. During follow-up, 44 cases of COVID-19 were reported, all mild, with no deaths or need for intensive care unit admission. Conclusions: Vaccination against SARS-CoV-2 demonstrated a favorable safety profile in patients with SLE, with a low frequency of serious adverse events. While analysis of disease activity revealed variations across vaccine platforms, most notably an increased proportion of moderate to high disease activity among those receiving ChAdOx-1 compared with CoronaVac and BNT162b2, the overall occurrence of COVID-19 during follow-up was limited to mild cases, with no severe outcomes. These findings highlight that, despite potential risks of disease exacerbation, the clear protection against severe COVID-19 supports vaccination as a beneficial strategy for this immunocompromised population.
Open AccessImpact of SARS-CoV-2 Vaccination on Disease Activity and Severity of COVID-19 Infection in Patients with Systemic Lupus Erythematosus: A Multicenter Cohort Study
Background: To prospectively evaluate the safety and clinical impact of SARS-CoV-2 vaccines in patients with systemic lupus erythematosus (SLE). Methods: Subanalysis of the Brazilian multicenter observational study “Safety, Effectiveness and Duration of Immunity after Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Inflammatory Diseases (SAFER)”, which included SLE patients vaccinated with CoronaVac, ChAdOx1, or BNT162b2. Patients with HIV infection, pregnant women, or those with immunosuppression not related to SLE were excluded. Safety data related to adverse events and underlying disease activity were assessed. Additionally, COVID-19 cases were monitored throughout the follow-up period. Results: The study included 373 patients with systemic lupus erythematosus (SLE), with a mean age of 36 years, the majority being women (89.8%). The most common adverse events after SARS-CoV-2 vaccination were injection site reactions and headache, observed both after the first and subsequent doses. The ChAdOx-1 vaccine was associated with a higher frequency of adverse events compared to CoronaVac. At baseline, 38.3% of patients were in remission, 32.8% had low disease activity, and 28.9% had moderate to high activity. Following CoronaVac vaccination, there was an increase in remission rates (from 34.6% to 51.1%) and a significant reduction in moderate to high activity (from 37.6% to 15.0%) after the first dose, with this reduction partially maintained after the second dose. In contrast, patients vaccinated with ChAdOx-1 showed an increase in moderate to high activity (from 14.5% to 38.2% after the first dose), a trend that persisted after the second dose. No statistically significant changes in disease activity were observed among those who received BNT162b2. During follow-up, 44 cases of COVID-19 were reported, all mild, with no deaths or need for intensive care unit admission. Conclusions: Vaccination against SARS-CoV-2 demonstrated a favorable safety profile in patients with SLE, with a low frequency of serious adverse events. While analysis of disease activity revealed variations across vaccine platforms, most notably an increased proportion of moderate to high disease activity among those receiving ChAdOx-1 compared with CoronaVac and BNT162b2, the overall occurrence of COVID-19 during follow-up was limited to mild cases, with no severe outcomes. These findings highlight that, despite potential risks of disease exacerbation, the clear protection against severe COVID-19 supports vaccination as a beneficial strategy for this immunocompromised population.
- 5 February 2025
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 39 (2) , 102039
Musculoskeletal manifestations in leprosy
- 5 February 2025
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 39 (2) , 102039
Musculoskeletal manifestations in leprosy